In this webinar, you will find a presentation by Dr. Joseph Shaw, Associate Principal Scientist, Discovery Sciences, R&D, AstraZeneca.
To deliver the next generation of medicines, drug discovery must modulate increasingly novel and challenging targets. Identification of chemical starting points and development of lead series against these targets requires faithfully capturing protein conformations and interactions in disease-relevant model systems. In this presentation, you will find case studies where Alpha CETSA has been applied to support lead generation across a broad range of AstraZeneca drug discovery projects.
Date: 20 October 2021
Presenter: Joseph Shaw, Associate Principal Scientist, Discovery Sciences, R&D, AstraZeneca
Duration: 58 minutes
CETSA® is a powerful technology measuring target engagement in live cells, and can be applied to quantify binding to endogenously expressed proteins within disease-relevant cell backgrounds. Using quantitative protein detection methods such as PerkinElmer Alpha®, CETSA can be applied in microtitre plates to enable application in Hit finding and Lead Generation.
